XML 68 R57.htm IDEA: XBRL DOCUMENT v3.6.0.2
Assets and Liabilities Measured at Fair Value (Details)
$ in Thousands
 1 Months Ended 12 Months Ended
Jul. 05, 2016
USD ($)
Sep. 30, 2015
USD ($)
Nov. 30, 2013
USD ($)
Dec. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
item
Dec. 31, 2014
USD ($)
Sep. 30, 2016
USD ($)
Jun. 30, 2016
USD ($)
Oct. 31, 2015
USD ($)
Financial assets and liabilities subject to fair value measurements                  
Transfer of assets from Level 1 to Level 2       $ 0          
Transfer of assets from Level 2 to Level 1       0          
Assets:                  
Fair value of assets       144,754 $ 145,206        
Trading securities       1,500 700        
Liabilities:                  
Contingent consideration payable       269,722 274,077        
Derivative liability       265          
Deferred compensation plan liability       1,479 667        
Fair value of liabilities       271,466 274,744        
Contingent consideration payable       269,722 274,077        
Contingent consideration payable                  
Balance, beginning of the period       274,077 10,700        
Additions, from business acquisitions         259,000        
Payment of contingent consideration in cash       (5,000)          
Payment of contingent consideration in stock       (6,115)          
Unrealized change in fair value change during the period, included in Statement of Operations       6,760 4,377 $ 100      
Balance, end of the period       269,722 $ 274,077 $ 10,700      
Foreign Currency Exchange Rate Exposure                  
Number Of Forward Contracts | item         0        
Non-cash changes in the fair value of derivative liability       (265)          
Other current liabilities                  
Foreign Currency Exchange Rate Exposure                  
Derivative liabilities       265     $ 300    
Callidus                  
Liabilities:                  
Contingent consideration payable     $ 10,600 9,700          
Contingent consideration payable     $ 10,600 9,700          
Discount rate (as a percent)     13.50%            
Scioderm                  
Liabilities:                  
Contingent consideration payable   $ 259,000   260,000          
Contingent consideration payable   $ 259,000   260,000          
MiaMed Inc                  
Liabilities:                  
Contingent consideration payable upon achievement of milestones $ 83,000                
Potential aggregate deal value 89,500                
Clinical and Regulatory Approval milestones | Callidus                  
Liabilities:                  
Contingent consideration payable       9,300          
Contingent consideration payable       9,300          
Clinical and Regulatory Approval milestones | Scioderm                  
Liabilities:                  
Contingent consideration payable       237,200          
Contingent consideration payable       237,200          
Revenue-based milestones | Scioderm                  
Liabilities:                  
Contingent consideration payable       22,800          
Contingent consideration payable       22,800          
Minimum | Clinical and Regulatory Approval milestones | Scioderm                  
Liabilities:                  
Discount rate (as a percent)   0.40%              
Minimum | Revenue-based milestones | Scioderm                  
Liabilities:                  
Discount rate (as a percent)   1.00%              
Maximum | Clinical and Regulatory Approval milestones | Scioderm                  
Liabilities:                  
Discount rate (as a percent)   1.10%              
Maximum | Revenue-based milestones | Scioderm                  
Liabilities:                  
Discount rate (as a percent)   2.20%              
Maximum | Clinical, Regulatory and Commercial milestones | MiaMed Inc                  
Liabilities:                  
Contingent consideration payable upon achievement of milestones $ 83,000                
Commercial paper                  
Assets:                  
Fair value of assets       68,390 $ 25,724        
Corporate debt securities                  
Assets:                  
Fair value of assets       74,535 118,474        
Certificate of deposit                  
Assets:                  
Fair value of assets         350        
Market exchanged mutual funds                  
Assets:                  
Fair value of assets       1,829 658        
Level 2                  
Assets:                  
Fair value of assets       144,754 145,206        
Liabilities:                  
Derivative liability       265          
Deferred compensation plan liability       1,479 667        
Fair value of liabilities       1,744 667        
Level 2 | Commercial paper                  
Assets:                  
Fair value of assets       68,390 25,724        
Level 2 | Corporate debt securities                  
Assets:                  
Fair value of assets       74,535 118,474        
Level 2 | Certificate of deposit                  
Assets:                  
Fair value of assets         350        
Level 2 | Market exchanged mutual funds                  
Assets:                  
Fair value of assets       1,829 658        
Level 3                  
Liabilities:                  
Contingent consideration payable       269,722 274,077        
Fair value of liabilities       269,722 274,077        
Contingent consideration payable       $ 269,722 $ 274,077        
Level 3 | Clinical and Regulatory Approval milestones | Probability weighted discounted cash flow | Callidus                  
Liabilities:                  
Discount rate (as a percent)       12.50%          
Level 3 | Revenue-based milestones | Monte Carlo | Scioderm                  
Liabilities:                  
Probability of achievement of milestones (as a percent)       66.50%          
Revenue volatility (as a percent)       58.00%          
Level 3 | Minimum | Clinical and Regulatory Approval milestones | Probability weighted discounted cash flow | Callidus                  
Liabilities:                  
Probability of achievement of milestones (as a percent)       30.40%          
Level 3 | Minimum | Clinical and Regulatory Approval milestones | Probability weighted discounted cash flow | Scioderm                  
Liabilities:                  
Discount rate (as a percent)       0.62%          
Probability of achievement of milestones (as a percent)       66.50%          
Level 3 | Minimum | Revenue-based milestones | Monte Carlo | Scioderm                  
Liabilities:                  
Discount rate (as a percent)       1.47%          
Level 3 | Maximum | Clinical and Regulatory Approval milestones | Probability weighted discounted cash flow | Callidus                  
Liabilities:                  
Probability of achievement of milestones (as a percent)       42.80%          
Level 3 | Maximum | Clinical and Regulatory Approval milestones | Probability weighted discounted cash flow | Scioderm                  
Liabilities:                  
Discount rate (as a percent)       3.80%          
Probability of achievement of milestones (as a percent)       100.00%          
Level 3 | Maximum | Revenue-based milestones | Monte Carlo | Scioderm                  
Liabilities:                  
Discount rate (as a percent)       2.55%          
Redmile Group | Note And Warrant Agreement 2015 [Member] | Private Placement Purchase Agreement                  
Financial assets and liabilities subject to fair value measurements                  
Proceeds from note and warrant purchase agreement                 $ 50,000
Redmile Group | Additional Note and Warrant Agreement June 2016 | Beneficial Owner | Private Placement Purchase Agreement                  
Financial assets and liabilities subject to fair value measurements                  
Proceeds from note and warrant purchase agreement               $ 30,000